With the FDA in turmoil, the ‘revolving door’ with industry is spinning faster
HHS Robert F. Kennedy Jr. has railed against a “revolving door” between drug companies and the FDA. But HHS’ actions now seem to be causing that door to spin faster.
Related Articles
Taking science’s temperature at the annual AACR meeting
You’re reading the web edition of AACR in 30 Seconds, STAT’s guide to the American Association for Cancer Research annual meeting. Sign up for email
Taking science’s temperature at the annual AACR meeting
You’re reading the web edition of AACR in 30 Seconds, STAT’s guide to the American Association for Cancer Research annual meeting. Sign up for email
Taking science’s temperature at the annual AACR meeting
You’re reading the web edition of AACR in 30 Seconds, STAT’s guide to the American Association for Cancer Research annual meeting. Sign up for email
STAT Summit West
Discover the impact of AI and emerging tech on health innovation Register now ABOUT BREAKTHROUGH WEST In Medicine, Artificial Intelligence Gets Real Yes,
NIH announces six new acting institute directors, many of them filling posts of ousted predecessors
The NIH announced six acting directors to run institutes, many to fill vacancies created by the ouster of predecessors
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
An Akeso lung cancer drug that beat Merck’s Keytruda in a head-to-head trial won approval in China this week
Rural health study is told it’s losing federal funds, and other major heart studies are worried
A federal health study that was examining the high burden of chronic disease in rural areas learned its funding has been cut off.
Day by day, how Trump is roiling science and health
STAT is tracking, day by day, what’s happened in the words of science and health during the first months of the Trump administration.
STAT readers on the animal wellness industry, drug price floors, and more
“It is sad to see pets die of something easily preventable. It’s even worse knowing that the owner was misinformed or misled in how to…
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
An Akeso lung cancer drug that beat Merck’s Keytruda in a head-to-head trial won approval in China this week
